{"gene":"RNASET2","run_date":"2026-06-10T06:43:37","timeline":{"discoveries":[{"year":2006,"finding":"RNASET2 is an acidic endoribonuclease with demonstrated catalytic (RNase) activity, as shown using purified recombinant protein expressed in the Baculovirus Expression Vector System and in a human cell line. The protein exists in multiple forms including a full-length glycosylated secreted form and proteolytic products, and localizes to lysosomes.","method":"Recombinant protein expression, enzymatic activity assay, subcellular fractionation/localization","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with purified recombinant protein, lysosomal localization by direct experiment, single lab but multiple orthogonal methods","pmids":["16620762"],"is_preprint":false},{"year":2005,"finding":"RNASET2 suppresses tumorigenesis and metastasis in ovarian cancer cell lines in vivo; this activity is not dependent on ribonuclease catalytic activity, as a double point mutation at the putative catalytic sites did not abolish tumor/metastasis suppression.","method":"In vivo xenograft assay, site-directed mutagenesis of catalytic residues, metastasis assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site mutagenesis with in vivo functional readout, single lab, replicated in subsequent papers","pmids":["15809705"],"is_preprint":false},{"year":2006,"finding":"Recombinant RNASET2 binds actin in vitro and inhibits angiogenesis (tube formation) induced by angiogenin, bFGF, and VEGF in HUVE cells; its antitumorigenic activity in colony formation assays is independent of enzymatic activity (catalytically inactive EI-RNASET2 retains this activity).","method":"Actin-binding assay (membrane blotting, crosslinking), HUVE cell tube formation assay, colony formation assay with enzymatically inactivated protein, xenograft model","journal":"Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal assays (binding, angiogenesis, colony formation, in vivo), single lab","pmids":["17109444"],"is_preprint":false},{"year":2010,"finding":"RNASET2 controls ovarian tumorigenesis in vivo through modification of the cellular microenvironment by inducing recruitment of immunocompetent cells of the monocyte/macrophage lineage; no direct effect on cancer cells was detected in several in vitro assays.","method":"In vivo xenograft tumor assay, in vitro functional assays (negative), immune cell recruitment analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo functional assay with immune cell characterization, single lab, multiple methods","pmids":["21189302"],"is_preprint":false},{"year":2011,"finding":"RNASET2 localizes to lysosomes in neurons; loss of rnaset2 in zebrafish leads to accumulation of undigested rRNA within lysosomes in brain neurons, white matter lesions, and accumulation of Amyloid precursor protein at sites of neurodegeneration, establishing familial cystic leukoencephalopathy as a lysosomal storage disorder with rRNA as the storage substrate.","method":"Zebrafish genetic mutant model, lysosomal localization by imaging, MRI microimaging, immunohistochemistry for APP and astrocyte markers","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in vertebrate model with multiple orthogonal readouts (lysosomal localization, rRNA accumulation, MRI, IHC), replicated across labs","pmids":["21199949"],"is_preprint":false},{"year":2011,"finding":"RNASET2 traffics through the trans-Golgi network and undergoes delivery to the plasma membrane for secretion. A second intracellular pool co-localizes with P-bodies, and this co-localization increases upon metabolic stress. Cells lacking RNASET2 show reduced numbers of P-bodies, indicating RNASET2 is involved in P-body formation.","method":"Fluorescence microscopy co-localization with TGN, plasma membrane, and P-body markers; temperature-sensitive VSVG trafficking assay; RNASET2 knockdown with P-body counting","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell imaging with multiple markers and functional loss-of-function, single lab, multiple orthogonal methods","pmids":["22188480"],"is_preprint":false},{"year":2014,"finding":"Overexpression of RNASET2 in melanocytes induces apoptosis via the TRAF2-caspases pathway; RNASET2 physically interacts with TRAF2, and overexpression inhibits TRAF2 expression.","method":"Overexpression in primary melanocytes, apoptosis assays (caspase pathway), co-immunoprecipitation of RNASET2-TRAF2 interaction","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP interaction plus overexpression functional assay, single lab, two methods","pmids":["24457966"],"is_preprint":false},{"year":2015,"finding":"RNASET2 is required for lipotoxic and oxidative stress-mediated cell death; haploinsufficiency confers increased antioxidant capacity and resistance to ROS-induced death. This function is critically dependent on catalytic activity (unlike its antitumorigenic role). Knockdown of RNASET2 in Drosophila fat body increases survival under oxidative stress.","method":"Loss-of-function genetic screen, haploinsufficiency experiments, ROS assays, knockdown in Drosophila (model organism ortholog)","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic screen plus in vivo Drosophila knockdown, catalytic-activity dependence established, single lab","pmids":["26206090"],"is_preprint":false},{"year":2017,"finding":"Mammalian mitochondrial RNA degradation occurs in the mitochondrial intermembrane space (IMS), not the matrix, and is carried out by IMS-localized RNASET2.","method":"Biochemical fractionation of mitochondrial compartments, knockdown and overexpression in HEK293 cells, RNA decay assays","journal":"Protein & cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — biochemical reconstitution with fractionation plus genetic knockdown/overexpression, multiple orthogonal methods, single lab","pmids":["28730546"],"is_preprint":false},{"year":2018,"finding":"Mitochondrial IMS RNASET2 also selectively degrades cytosolic rRNAs associated with the mitochondrial outer membrane; this degradation activity positively affects nuclear transcription of rRNAs (compensatory feedback) and influences protein translation inside and outside mitochondria.","method":"Biochemical fractionation, rRNA decay measurements, genetic knockdown and overexpression in HEK293 and mouse cells, protein translation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal biochemical and genetic methods in two cell systems, single lab, mechanistically novel extension of prior finding","pmids":["30385512"],"is_preprint":false},{"year":2018,"finding":"RNASET2 impairs sperm motility by interacting with AKAP4 in the sperm tail, reducing PKA activity, PI3K activity, and intracellular calcium levels; cAMP supplementation rescues motility.","method":"Co-immunoprecipitation, mass spectrometry, co-localization by confocal microscopy, RNASET2 protein incubation assay, PKA/PI3K/calcium measurement","journal":"Reproduction (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus MS identification plus functional rescue by cAMP, single lab, multiple methods","pmids":["29581387"],"is_preprint":false},{"year":2021,"finding":"FBXO6, a substrate recognition subunit of an SCF E3 ubiquitin ligase complex, directly interacts with RNASET2 and promotes its K48-linked polyubiquitination via its FBA domain, leading to proteasomal degradation of RNASET2.","method":"Co-immunoprecipitation, ubiquitination assays, domain mapping (FBA domain), proteasome inhibitor experiments, clinical sample correlation","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct ubiquitination assay with domain mapping, co-IP, and proteasome dependence established, single lab with multiple orthogonal methods","pmids":["33767133"],"is_preprint":false},{"year":2021,"finding":"Rnaset2-/- mice (CRISPR/Cas9-generated) exhibit upregulation of interferon-stimulated genes and IFNAR1-dependent neuroinflammation, with infiltration of CD8+ effector memory T cells and inflammatory monocytes into grey and white matter; single-nuclei RNA sequencing revealed homeostatic dysfunctions in glial cells and neurons.","method":"CRISPR/Cas9 knockout mice, ISG expression profiling, immune cell characterization by flow cytometry/IHC, IFNAR1 blocking, single-nuclei RNA sequencing","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout model with multiple independent readouts including snRNA-seq and IFNAR1 blocking epistasis, rigorous study","pmids":["34764281"],"is_preprint":false},{"year":2020,"finding":"Mutant microglia (in rnaset2-deficient zebrafish) display engorged morphology filled with undigested apoptotic cells and undigested substrate; microglia-specific depletion and rescue experiments identified microglia as the cellular driver of the embryonic neuroinflammatory phenotype in RNASET2-deficient leukoencephalopathy.","method":"Zebrafish mutant model, live confocal imaging, electron microscopy, microglia-specific depletion and macrophage rescue experiments","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic model with live imaging, EM, and cell-specific rescue experiments, rigorous mechanistic dissection","pmids":["32212285"],"is_preprint":false},{"year":2015,"finding":"RNASET2 expression increases following stress induction; changes in RNASET2 levels affect actin cytoskeleton organization, cell adhesion, and motility in ovarian cancer cells in vitro, suggesting cell-autonomous oncosuppressive mechanisms distinct from its microenvironmental role.","method":"Stress induction assays, overexpression/knockdown in ovarian cancer cells, actin cytoskeleton imaging, cell adhesion and motility assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple cell biological readouts, single lab, but indirect mechanism","pmids":["25797262"],"is_preprint":false},{"year":2015,"finding":"RNASET2 interacts with shootin1 (an axon outgrowth protein) in vitro as identified by human proteome microarray and confirmed by co-immunoprecipitation; recombinant RNASET2 alters actin network organization in melanocytes and inhibits A375 cell migration.","method":"Human proteome microarray, co-immunoprecipitation, actin network imaging, cell migration assay","journal":"Journal of dermatological science","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — proteome microarray identification with Co-IP confirmation and functional assays, single lab","pmids":["26293343"],"is_preprint":false},{"year":2014,"finding":"A truncated RNASET2 lacking RNase activity (trT2-50, starting at E50) retains actin-binding activity and inhibits angiogenesis and tumorigenesis; trT2-50 binds cell-surface actin and forms a complex with actin in vitro, co-localizes with angiogenin, and disrupts the intracellular actin network of HUVECs.","method":"Truncation mutagenesis, in vitro actin-binding assay, HUVE cell tube formation assay, immunofluorescence, xenograft tumor assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of actin binding with truncation mutant plus functional assays, single lab","pmids":["25426551"],"is_preprint":false},{"year":2018,"finding":"RNASET2 protein affects macrophage polarization in vitro, promoting a shift toward M1-like (anti-tumor) phenotype and away from M2-like phenotype, as demonstrated by in vitro macrophage polarization assays.","method":"In vitro macrophage polarization assay with recombinant RNASET2, transcriptional profiling of M1/M2 markers","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — in vitro assay with recombinant protein, single lab, functional readout with multiple markers","pmids":["30218741"],"is_preprint":false},{"year":2020,"finding":"Murine Rnaset2 overexpression in syngeneic tumor models leads to recruitment of CD86+ M1 macrophages, inhibition of MDSCs and M2 macrophages, subsequent expansion of intratumoral CD8+ T cells, and long-term tumor rejection with T cell memory response upon re-challenge.","method":"Syngeneic mouse tumor model, immune cell phenotyping by flow cytometry, re-challenge assay","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo syngeneic model with immune cell characterization and re-challenge, single lab","pmids":["32197460"],"is_preprint":false},{"year":2023,"finding":"RNASET2 deficiency leads to accumulation of cholesterol by hindering RNA degradation into uridine, reducing UTP levels, restraining glucuronate metabolism and UDP-glucuronosyltransferase (UGT1A1) expression, causing decreased bile acid glucuronidation and cholesterol accumulation. Accumulated cholesterol promotes MET receptor-mediated HCC metastasis, which can be reversed by MET knockdown or savolitinib.","method":"RNASET2 knockout cells and mouse models, metabolomics (uridine/UTP/glucuronate measurement), UGT1A1 expression analysis, cholesterol measurement, MET activation assay, shRNA/pharmacological MET inhibition rescue","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-step metabolic pathway established with genetic KO plus rescue experiments, single lab, multiple orthogonal methods","pmids":["39903758"],"is_preprint":false},{"year":2023,"finding":"MSI2 (Musashi-2) binds FBXO6 to induce Rnaset2 ubiquitination; MSI2 knockdown inhibits VSMC proliferation and migration and suppresses chemokine signaling via the FBXO6/Rnaset2 axis in atherosclerosis.","method":"RNA-binding protein immunoprecipitation, co-immunoprecipitation, siRNA knockdown, proliferation/migration assays, in vivo atherosclerosis mouse model","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and Co-IP with functional rescue, single lab","pmids":["37633478"],"is_preprint":false},{"year":2019,"finding":"RNASET2 expression in epithelial ovarian cancer cells negatively affects growth capability by altering cell interaction with the extracellular matrix, resulting in decreased Src kinase activation, as shown by RNASET2 silencing and overexpression experiments.","method":"RNASET2 silencing and overexpression in EOC cell lines, Src activation assay (phospho-Src), ECM adhesion and growth assays","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — loss- and gain-of-function with defined signaling readout (Src), single lab","pmids":["30813308"],"is_preprint":false},{"year":2021,"finding":"Hypoxia enhances RNASET2 expression and secretion in human monocyte-derived dendritic cells via the PI3K/AKT pathway; this expression is almost completely abolished by TLR4 ligand LPS, and parallels HIF-1α accumulation.","method":"Hypoxia treatment of primary DCs, RNASET2 ELISA, PI3K/AKT inhibitor experiments, HIF-1α measurement","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological pathway dissection plus secretion measurement, single lab","pmids":["34299186"],"is_preprint":false},{"year":2025,"finding":"Macrophage-secreted RNASET2 enters muscle stem cells (MuSCs) via the mannose receptor, binds to SLK (Ste20-like kinase), which triggers phosphorylation-mediated activation of N-WASP through Paxillin phosphorylation, enabling actin bundling required for MuSC fusion; macrophages deficient in RNAseT2 show fusion defects and smaller myofibers in vivo.","method":"Recombinant protein treatment, mannose receptor blocking, co-immunoprecipitation of RNASET2-SLK interaction, N-WASP/Paxillin phosphorylation assays, macrophage-specific knockout in mouse and zebrafish, in vivo overexpression","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical interaction (Co-IP), receptor-mediated entry, kinase pathway mutagenesis, in vivo rescue in two model organisms, multiple orthogonal methods","pmids":["41980967"],"is_preprint":false},{"year":2024,"finding":"RNASET2 is identified as a lysosomal RNase; cells lacking RNASET2 (together with PLD3 and RNase A family members) accumulate large amounts of lysosomal RNA, establishing RNASET2 as one of the enzymatic effectors of lysosomal RNA degradation.","method":"Lysosomal fractionation and RNA profiling, genetic knockout of RNASET2 and other lysosomal RNases, RNA accumulation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with direct lysosomal RNA measurement, preprint, single lab","pmids":[],"is_preprint":true},{"year":2024,"finding":"Transplanted macrophages engraft in rnaset2-deficient zebrafish brains, adopt a microglial phenotype, clear apoptotic cells, rescue antiviral immune overactivation (confirmed by RNA sequencing), and restore normal motor behavior, establishing microglia as the cellular driver of neuropathology in RNASET2 deficiency.","method":"Macrophage transplantation into zebrafish embryos, live imaging, tissue clearing, RNA sequencing, behavioral assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-specific rescue with multiple readouts (imaging, transcriptomics, behavior), rigorous mechanistic attribution to microglia","pmids":["38753517"],"is_preprint":false},{"year":2018,"finding":"RNASET2 is localized in primary and tertiary granules of neutrophils and is released in association with neutrophil extracellular traps (NETs) upon PMA, Nigericin, or soluble immune complex stimulation.","method":"Immunofluorescence co-localization with granule markers, NET induction assays, co-localization of RNASET2 with NET markers","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct co-localization experiments with multiple stimuli, single lab","pmids":["39500942"],"is_preprint":false},{"year":2022,"finding":"Recombinant RNASET2 reduces IFN-γ secretion in T cells when added exogenously or overexpressed; disease-risk variant rs2149092 affects allele-specific RNASET2 expression through transcriptional and post-transcriptional mechanisms.","method":"T cell activation assays, RNASET2 overexpression and recombinant protein treatment, cytokine ELISA, allele-specific expression assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function and recombinant protein with cytokine readout, single lab","pmids":["36466822"],"is_preprint":false},{"year":2025,"finding":"RNASET2 knockdown in a 3D inflammatory thyrocyte spheroid model heightens susceptibility to inflammatory cell death and cytokine expression; recombinant RNASET2 rescue mitigates inflammation and apoptosis, confirming a functional protective role.","method":"siRNA knockdown, recombinant RNASET2 rescue, 3D spheroid inflammatory model, apoptosis and cytokine assays","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with protein rescue in defined model, single lab, two orthogonal approaches","pmids":["41704487"],"is_preprint":false}],"current_model":"RNASET2 is an evolutionarily conserved, lysosome- and IMS-localized acidic endoribonuclease that degrades rRNA, mitochondrial RNA, and cytosolic rRNAs on the mitochondrial outer membrane; its catalytic activity is required for lysosomal RNA homeostasis and ROS-dependent cell death, but dispensable for its tumor-suppressive and antiangiogenic functions, which instead operate through actin cytoskeleton remodeling (via SLK/N-WASP activation and actin binding), ECM-mediated Src signaling suppression, recruitment and M1 polarization of macrophages, TRAF2-caspase apoptosis induction, and modulation of T cell IFN-γ; RNASET2 protein stability is regulated by FBXO6-mediated K48-linked ubiquitination and proteasomal degradation, and its deficiency in neurons causes lysosomal rRNA accumulation, microglial dysfunction, and an IFNAR1-dependent type I interferon-driven leukoencephalopathy."},"narrative":{"mechanistic_narrative":"RNASET2 is an evolutionarily conserved acidic endoribonuclease that degrades RNA in multiple subcellular compartments and underpins both intracellular RNA homeostasis and a set of catalysis-independent extracellular signaling functions [PMID:16620762, PMID:15809705]. As an enzyme, it is a glycosylated, secreted RNase that localizes to lysosomes [PMID:16620762] and functions as an effector of lysosomal RNA degradation; its loss causes accumulation of undigested rRNA within neuronal lysosomes, defining RNASET2-deficient cystic leukoencephalopathy as a lysosomal storage disorder with rRNA as the storage substrate [PMID:21199949]. A distinct pool resides in the mitochondrial intermembrane space, where it degrades mitochondrial RNA and outer-membrane-associated cytosolic rRNAs, feeding back on nuclear rRNA transcription and translation [PMID:28730546, PMID:30385512]. This catalytic activity is required for lipotoxic/oxidative-stress-mediated cell death [PMID:26206090] but is dispensable for RNASET2's tumor- and metastasis-suppressive and antiangiogenic activities, which instead depend on actin binding: catalytically inactive and N-terminally truncated forms retain actin-binding, antiangiogenic, and antitumorigenic activity [PMID:15809705, PMID:17109444, PMID:25426551]. Secreted RNASET2 acts non-cell-autonomously to remodel the tumor and tissue microenvironment, suppressing Src signaling through altered ECM interaction [PMID:30813308], recruiting monocyte/macrophages and driving M1 polarization with downstream CD8+ T cell expansion and tumor rejection [PMID:21189302, PMID:32197460], and entering recipient cells via the mannose receptor to bind SLK and activate N-WASP-dependent actin bundling required for muscle stem cell fusion [PMID:41980967]. RNASET2 protein abundance is controlled by FBXO6, which directly binds it and catalyzes K48-linked polyubiquitination and proteasomal degradation [PMID:33767133]. In the nervous system, RNASET2 deficiency produces engorged, dysfunctional microglia that fail to clear apoptotic substrate and drive an IFNAR1-dependent type I interferon neuroinflammation, with microglia established as the cellular driver via cell-specific depletion and macrophage rescue [PMID:34764281, PMID:32212285, PMID:38753517].","teleology":[{"year":2005,"claim":"Established that RNASET2's tumor- and metastasis-suppressive activity is separable from its predicted enzymatic role, a finding that reframed the protein as more than an RNase.","evidence":"in vivo ovarian cancer xenograft and metastasis assays with catalytic-site double point mutants","pmids":["15809705"],"confidence":"Medium","gaps":["Did not identify the molecular mediator of catalysis-independent suppression","Mechanism of microenvironmental action not yet defined"]},{"year":2006,"claim":"Confirmed RNASET2 is a bona fide acidic endoribonuclease and a glycosylated, secreted, lysosomally localized protein, anchoring its enzymatic and trafficking identity.","evidence":"purified recombinant protein enzymatic assay plus subcellular fractionation/localization","pmids":["16620762"],"confidence":"High","gaps":["In vivo RNA substrates not defined","Relationship between secreted and lysosomal pools unresolved"]},{"year":2006,"claim":"Identified actin binding as a candidate catalysis-independent effector mechanism by showing RNASET2 binds actin and inhibits angiogenesis induced by multiple growth factors.","evidence":"in vitro actin-binding assays, HUVE tube formation, colony formation with enzymatically inactivated protein, xenografts","pmids":["17109444"],"confidence":"Medium","gaps":["Did not map the actin-binding region","Link between actin binding and antiangiogenesis correlative"]},{"year":2010,"claim":"Showed the oncosuppressive effect operates non-cell-autonomously through recruitment of monocyte/macrophage-lineage immune cells, identifying a microenvironmental mechanism.","evidence":"in vivo ovarian xenografts with immune cell recruitment analysis and negative in vitro cancer-cell assays","pmids":["21189302"],"confidence":"Medium","gaps":["Macrophage polarization state not yet characterized","Signal recruiting immune cells unknown"]},{"year":2011,"claim":"Established RNASET2 deficiency as a lysosomal storage disorder by showing loss causes accumulation of undigested rRNA in neuronal lysosomes with white matter pathology.","evidence":"zebrafish genetic mutant with lysosomal imaging, MRI microimaging, and APP/astrocyte IHC","pmids":["21199949"],"confidence":"High","gaps":["Cellular driver of neuropathology not yet pinpointed","Inflammatory mechanism not addressed"]},{"year":2011,"claim":"Extended RNASET2 localization to the secretory pathway and P-bodies, linking it to cytoplasmic RNA granule biology under metabolic stress.","evidence":"fluorescence co-localization with TGN/PM/P-body markers, VSVG trafficking, and knockdown P-body counting","pmids":["22188480"],"confidence":"Medium","gaps":["Mechanism of P-body involvement undefined","Does not connect P-body role to enzymatic or microenvironmental functions"]},{"year":2014,"claim":"Demonstrated a pro-apoptotic activity via direct TRAF2 interaction, and confirmed actin remodeling by an RNase-dead truncation, separating catalytic from cytoskeletal functions in melanocytes.","evidence":"overexpression apoptosis assays with TRAF2 Co-IP; truncation mutagenesis with in vitro actin-binding and angiogenesis/tumor assays","pmids":["24457966","25426551"],"confidence":"Medium","gaps":["TRAF2 interaction shown by single Co-IP without structural detail","Physiological context of TRAF2-caspase axis unclear"]},{"year":2015,"claim":"Defined a catalysis-dependent function in stress-induced cell death and connected RNASET2 levels to actin organization, adhesion, and motility, splitting its activities into distinct mechanistic branches.","evidence":"loss-of-function/haploinsufficiency ROS assays, Drosophila fat-body knockdown; ovarian cancer cell actin/adhesion/motility assays; shootin1 interaction by proteome microarray and Co-IP","pmids":["26206090","25797262","26293343"],"confidence":"Medium","gaps":["Substrate driving ROS-dependent death not identified","Mechanistic link between shootin1/actin binding and motility incomplete"]},{"year":2017,"claim":"Localized a functional pool of RNASET2 to the mitochondrial intermembrane space and assigned it responsibility for mitochondrial RNA degradation, revealing an unexpected mitochondrial compartment role.","evidence":"mitochondrial sub-compartment fractionation with knockdown/overexpression and RNA decay assays in HEK293","pmids":["28730546"],"confidence":"High","gaps":["Import mechanism into IMS unknown","Regulation of compartment-specific targeting undefined"]},{"year":2018,"claim":"Expanded mitochondrial RNASET2's role to degradation of outer-membrane-associated cytosolic rRNAs with compensatory feedback on nuclear rRNA transcription and translation, linking it to global RNA economy.","evidence":"fractionation, rRNA decay measurements, knockdown/overexpression in HEK293 and mouse cells, translation assays","pmids":["30385512"],"confidence":"High","gaps":["Mechanism of feedback to nuclear transcription not resolved","Selectivity for OMM-associated rRNAs not explained"]},{"year":2018,"claim":"Connected RNASET2 to macrophage polarization and a sperm-tail AKAP4 signaling axis, broadening its extracellular and tissue-specific functional repertoire.","evidence":"in vitro macrophage M1/M2 polarization with recombinant protein; sperm Co-IP/MS with AKAP4 and PKA/PI3K/calcium readouts plus cAMP rescue","pmids":["30218741","29581387"],"confidence":"Medium","gaps":["Receptor mediating macrophage effect not identified here","Physiological relevance of sperm AKAP4 interaction unclear"]},{"year":2019,"claim":"Identified an ECM-dependent, cell-autonomous oncosuppressive branch acting through reduced Src kinase activation, refining the non-enzymatic mechanism.","evidence":"silencing/overexpression in EOC lines with phospho-Src, ECM adhesion, and growth assays","pmids":["30813308"],"confidence":"Medium","gaps":["Molecular link between RNASET2 and ECM not defined","Connection to actin-binding branch not established"]},{"year":2020,"claim":"Demonstrated in vivo that RNASET2 drives M1 macrophage recruitment, MDSC/M2 suppression, CD8+ T cell expansion, and durable immune memory, and established microglia as the cellular driver of leukoencephalopathy.","evidence":"syngeneic mouse tumor model with immune phenotyping and re-challenge; zebrafish microglia-specific depletion/rescue with live imaging and EM","pmids":["32197460","32212285"],"confidence":"Medium","gaps":["Receptor/signal for immune recruitment unresolved","Whether tumor and CNS macrophage roles share a mechanism unknown"]},{"year":2021,"claim":"Defined post-translational control of RNASET2 abundance via FBXO6-mediated K48 ubiquitination and proteasomal degradation, and established an IFNAR1-dependent type I interferon mechanism for the neuroinflammatory disease.","evidence":"Co-IP, ubiquitination assays, FBA domain mapping, proteasome inhibition; CRISPR knockout mice with ISG profiling, IFNAR1 blocking, and snRNA-seq","pmids":["33767133","34764281"],"confidence":"High","gaps":["Signal triggering FBXO6 recognition not defined","Source of the interferon-stimulating ligand (accumulated RNA) not directly proven"]},{"year":2023,"claim":"Connected RNASET2 enzymatic RNA degradation to a uridine-glucuronate-cholesterol metabolic axis driving MET-dependent HCC metastasis, and placed the FBXO6/RNASET2 axis under MSI2 control in vascular disease.","evidence":"KO cells/mice with metabolomics, UGT1A1 and cholesterol analysis, MET inhibition rescue; RIP/Co-IP and atherosclerosis mouse model for MSI2-FBXO6","pmids":["39903758","37633478"],"confidence":"Medium","gaps":["Quantitative contribution of RNA-derived uridine to cholesterol pool uncertain","Tissue specificity of MSI2/FBXO6 regulation not generalized"]},{"year":2025,"claim":"Resolved a receptor-to-cytoskeleton signaling pathway: macrophage-secreted RNASET2 enters target cells via the mannose receptor and binds SLK to activate N-WASP-driven actin bundling required for muscle stem cell fusion, and confirmed microglial rescue of CNS pathology.","evidence":"recombinant protein, mannose receptor blocking, RNASET2-SLK Co-IP, N-WASP/Paxillin phospho assays, macrophage-specific KO in mouse and zebrafish; macrophage transplantation into zebrafish with imaging, RNA-seq, behavior","pmids":["41980967","38753517"],"confidence":"High","gaps":["Whether the SLK/N-WASP pathway underlies the antitumor actin functions not tested","Structural basis of RNASET2-SLK interaction unknown"]},{"year":null,"claim":"It remains unresolved how RNASET2 partitions between its catalysis-dependent RNA-homeostasis roles and its catalysis-independent secreted signaling functions, and whether a unifying molecular trigger directs the protein to lysosome, mitochondrial IMS, or extracellular signaling fates.","evidence":"no single study in the corpus reconciles the compartment-specific and catalysis-independent activities","pmids":[],"confidence":"Low","gaps":["No structural model linking actin/SLK binding to catalytic domain","Mechanism directing subcellular partitioning unknown","Identity of the immunostimulatory RNA species in disease not directly defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,8,9,24]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[2,16]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0,4,24]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[8,9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,23,26]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[8,9,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,12,18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[11]}],"complexes":[],"partners":["TRAF2","FBXO6","AKAP4","SLK","SHTN1","MSI2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00584","full_name":"Ribonuclease T2","aliases":["Ribonuclease 6"],"length_aa":256,"mass_kda":29.5,"function":"Ribonuclease that plays an essential role in innate immune response by recognizing and degrading RNAs from microbial pathogens that are subsequently sensed by TLR8 (PubMed:31778653). Cleaves preferentially single-stranded RNA molecules between purine and uridine residues, which critically contributes to the supply of catabolic uridine and the generation of purine-2',3'-cyclophosphate-terminated oligoribonucleotides (PubMed:31778653, PubMed:38697119). In turn, RNase T2 degradation products promote the RNA-dependent activation of TLR8 (PubMed:31778653). In plasmacytoid dendritic cells, it cooperates with PLD3 or PLD4 5'->3' exonucleases to process RNA fragments and release 2',3'-cyclic guanosine monophosphate (2',3'-cGMP), a potent stimulatory ligand for TLR7 (PubMed:38697119). Also plays a key role in degradation of mitochondrial RNA and processing of non-coding RNA imported from the cytosol into mitochondria (PubMed:28730546, PubMed:30184494). Participates as well in degradation of mitochondrion-associated cytosolic rRNAs (PubMed:30385512)","subcellular_location":"Secreted; Lysosome lumen; Endoplasmic reticulum lumen; Mitochondrion intermembrane space","url":"https://www.uniprot.org/uniprotkb/O00584/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RNASET2","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RNASET2","total_profiled":1310},"omim":[{"mim_id":"614932","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 13; COXPD13","url":"https://www.omim.org/entry/614932"},{"mim_id":"612951","title":"LEUKOENCEPHALOPATHY, CYSTIC, WITHOUT MEGALENCEPHALY","url":"https://www.omim.org/entry/612951"},{"mim_id":"612944","title":"RIBONUCLEASE T2; RNASET2","url":"https://www.omim.org/entry/612944"},{"mim_id":"606579","title":"VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1; VAMAS1","url":"https://www.omim.org/entry/606579"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RNASET2"},"hgnc":{"alias_symbol":["RNASE6PL","FLJ10907","bA514O12.3"],"prev_symbol":[]},"alphafold":{"accession":"O00584","domains":[{"cath_id":"3.90.730.10","chopping":"36-248","consensus_level":"high","plddt":92.3217,"start":36,"end":248}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00584","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00584-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00584-F1-predicted_aligned_error_v6.png","plddt_mean":86.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RNASET2","jax_strain_url":"https://www.jax.org/strain/search?query=RNASET2"},"sequence":{"accession":"O00584","fasta_url":"https://rest.uniprot.org/uniprotkb/O00584.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00584/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00584"}},"corpus_meta":[{"pmid":"19525954","id":"PMC_19525954","title":"RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19525954","citation_count":123,"is_preprint":false},{"pmid":"21199949","id":"PMC_21199949","title":"rnaset2 mutant zebrafish model familial cystic leukoencephalopathy and reveal a role for RNase T2 in degrading ribosomal RNA.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21199949","citation_count":95,"is_preprint":false},{"pmid":"16620762","id":"PMC_16620762","title":"Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins.","date":"2006","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/16620762","citation_count":58,"is_preprint":false},{"pmid":"17109444","id":"PMC_17109444","title":"A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification, and characterization.","date":"2006","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17109444","citation_count":56,"is_preprint":false},{"pmid":"21189302","id":"PMC_21189302","title":"Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21189302","citation_count":55,"is_preprint":false},{"pmid":"15809705","id":"PMC_15809705","title":"Tumor and metastasis suppression by the human RNASET2 gene.","date":"2005","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15809705","citation_count":53,"is_preprint":false},{"pmid":"24457966","id":"PMC_24457966","title":"Stress-induced RNASET2 overexpression mediates melanocyte apoptosis via the TRAF2 pathway in vitro.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24457966","citation_count":42,"is_preprint":false},{"pmid":"30368505","id":"PMC_30368505","title":"AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech.","date":"2018","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30368505","citation_count":39,"is_preprint":false},{"pmid":"32212285","id":"PMC_32212285","title":"The failure of microglia to digest developmental apoptotic cells contributes to the pathology of RNASET2-deficient leukoencephalopathy.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32212285","citation_count":38,"is_preprint":false},{"pmid":"26206090","id":"PMC_26206090","title":"RNASET2 is required for ROS propagation during oxidative stress-mediated cell death.","date":"2015","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26206090","citation_count":36,"is_preprint":false},{"pmid":"33767133","id":"PMC_33767133","title":"FBXO6-mediated RNASET2 ubiquitination and degradation governs the development of ovarian cancer.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33767133","citation_count":33,"is_preprint":false},{"pmid":"28730546","id":"PMC_28730546","title":"Mammalian mitochondrial RNAs are degraded in the mitochondrial intermembrane space by RNASET2.","date":"2017","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/28730546","citation_count":33,"is_preprint":false},{"pmid":"34764281","id":"PMC_34764281","title":"Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34764281","citation_count":32,"is_preprint":false},{"pmid":"18543608","id":"PMC_18543608","title":"RNASET2 as a tumor antagonizing gene in a melanoma cancer model.","date":"2008","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/18543608","citation_count":31,"is_preprint":false},{"pmid":"28070637","id":"PMC_28070637","title":"Human recombinant RNASET2-induced inflammatory response and connective tissue remodeling in the medicinal leech.","date":"2017","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/28070637","citation_count":28,"is_preprint":false},{"pmid":"29581387","id":"PMC_29581387","title":"RNASET2 impairs the sperm motility via PKA/PI3K/calcium signal pathways.","date":"2018","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29581387","citation_count":27,"is_preprint":false},{"pmid":"31749812","id":"PMC_31749812","title":"Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31749812","citation_count":27,"is_preprint":false},{"pmid":"30218741","id":"PMC_30218741","title":"The human RNASET2 protein affects the polarization pattern of human macrophages in vitro.","date":"2018","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30218741","citation_count":26,"is_preprint":false},{"pmid":"25797262","id":"PMC_25797262","title":"Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25797262","citation_count":26,"is_preprint":false},{"pmid":"22188480","id":"PMC_22188480","title":"Intracellular trafficking of RNASET2, a novel component of P-bodies.","date":"2011","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22188480","citation_count":23,"is_preprint":false},{"pmid":"24365605","id":"PMC_24365605","title":"Molecular characterization and immune modulation properties of Clonorchis sinensis-derived RNASET2.","date":"2013","source":"Parasites & vectors","url":"https://pubmed.ncbi.nlm.nih.gov/24365605","citation_count":23,"is_preprint":false},{"pmid":"30385512","id":"PMC_30385512","title":"Regulation of mitochondrion-associated cytosolic ribosomes by mammalian mitochondrial ribonuclease T2 (RNASET2).","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30385512","citation_count":22,"is_preprint":false},{"pmid":"32197460","id":"PMC_32197460","title":"Overexpression of Murine Rnaset2 in a Colon Syngeneic Mouse Carcinoma Model Leads to Rebalance of Intra-Tumor M1/M2 Macrophage Ratio, Activation of T Cells, Delayed Tumor Growth, and Rejection.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32197460","citation_count":21,"is_preprint":false},{"pmid":"29752287","id":"PMC_29752287","title":"RNaseT2 knockout rats exhibit hippocampal neuropathology and deficits in memory.","date":"2018","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29752287","citation_count":19,"is_preprint":false},{"pmid":"34299186","id":"PMC_34299186","title":"Hypoxia Enhances the Expression of RNASET2 in Human Monocyte-Derived Dendritic Cells: Role of PI3K/AKT Pathway.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299186","citation_count":19,"is_preprint":false},{"pmid":"32210967","id":"PMC_32210967","title":"Antimicrobial Role of RNASET2 Protein During Innate Immune Response in the Medicinal Leech Hirudo verbana.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32210967","citation_count":18,"is_preprint":false},{"pmid":"31349848","id":"PMC_31349848","title":"RNASET2-deficient leukoencephalopathy mimicking congenital CMV infection and Aicardi-Goutieres syndrome: a case report with a novel pathogenic variant.","date":"2019","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31349848","citation_count":15,"is_preprint":false},{"pmid":"21646684","id":"PMC_21646684","title":"Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells.","date":"2011","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/21646684","citation_count":14,"is_preprint":false},{"pmid":"19382914","id":"PMC_19382914","title":"Chromosome 6 encoded RNaseT2 protein is a cell growth regulator.","date":"2009","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19382914","citation_count":12,"is_preprint":false},{"pmid":"23258633","id":"PMC_23258633","title":"RNASET2 in human spermatozoa and seminal plasma: a novel relevant indicator for asthenozoospermia.","date":"2012","source":"Andrology","url":"https://pubmed.ncbi.nlm.nih.gov/23258633","citation_count":12,"is_preprint":false},{"pmid":"27014725","id":"PMC_27014725","title":"Human recombinant RNASET2: A potential anti-cancer drug.","date":"2016","source":"Oncoscience","url":"https://pubmed.ncbi.nlm.nih.gov/27014725","citation_count":12,"is_preprint":false},{"pmid":"25928629","id":"PMC_25928629","title":"RNASET2 tag SNP but not CCR6 polymorphisms is associated with autoimmune thyroid diseases in the Chinese Han population.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25928629","citation_count":11,"is_preprint":false},{"pmid":"36728187","id":"PMC_36728187","title":"HIF2α-induced upregulation of RNASET2 promotes triglyceride synthesis and enhances cell migration in clear cell renal cell carcinoma.","date":"2023","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/36728187","citation_count":10,"is_preprint":false},{"pmid":"30813308","id":"PMC_30813308","title":"A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30813308","citation_count":10,"is_preprint":false},{"pmid":"28568286","id":"PMC_28568286","title":"RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease.","date":"2017","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/28568286","citation_count":10,"is_preprint":false},{"pmid":"21446958","id":"PMC_21446958","title":"Comparison of the baculovirus-insect cell and Pichia pastoris heterologous systems for the expression of the human tumor suppressor protein RNASET2.","date":"2011","source":"Biotechnology and applied biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21446958","citation_count":10,"is_preprint":false},{"pmid":"25426551","id":"PMC_25426551","title":"Human recombinant truncated RNASET2, devoid of RNase activity; A potential cancer therapeutic agent.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25426551","citation_count":9,"is_preprint":false},{"pmid":"26293343","id":"PMC_26293343","title":"Rnaset2 inhibits melanocyte outgrowth possibly through interacting with shootin1.","date":"2015","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/26293343","citation_count":8,"is_preprint":false},{"pmid":"36012339","id":"PMC_36012339","title":"Human RNASET2: A Highly Pleiotropic and Evolutionary Conserved Tumor Suppressor Gene Involved in the Control of Ovarian Cancer Pathogenesis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012339","citation_count":8,"is_preprint":false},{"pmid":"29763721","id":"PMC_29763721","title":"New insights into hypoxia-related mechanisms involved in different microvascular patterns of bronchopulmonary carcinoids and poorly differentiated neuroendocrine carcinomas. Role of ribonuclease T2 (RNASET2) and HIF-1α.","date":"2018","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29763721","citation_count":8,"is_preprint":false},{"pmid":"25815360","id":"PMC_25815360","title":"Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization.","date":"2014","source":"Oncoscience","url":"https://pubmed.ncbi.nlm.nih.gov/25815360","citation_count":8,"is_preprint":false},{"pmid":"22732457","id":"PMC_22732457","title":"RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis.","date":"2012","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/22732457","citation_count":7,"is_preprint":false},{"pmid":"32295832","id":"PMC_32295832","title":"Zebrafish disease model of human RNASET2-deficient cystic leukoencephalopathy displays abnormalities in early microglia.","date":"2020","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/32295832","citation_count":7,"is_preprint":false},{"pmid":"36180758","id":"PMC_36180758","title":"A potential role of human RNASET2 overexpression in the pathogenesis of Graves' disease.","date":"2022","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/36180758","citation_count":6,"is_preprint":false},{"pmid":"36054934","id":"PMC_36054934","title":"Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.","date":"2022","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/36054934","citation_count":6,"is_preprint":false},{"pmid":"39035989","id":"PMC_39035989","title":"PTGES2 and RNASET2 identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma: insights from proteome-wide mendelian randomization, colocalization, and MR-PheWAS analyses.","date":"2024","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39035989","citation_count":6,"is_preprint":false},{"pmid":"39903758","id":"PMC_39903758","title":"RNASET2 Deficiency Induces Hepatocellular Carcinoma Metastasis through Cholesterol-Triggered MET Activation.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39903758","citation_count":5,"is_preprint":false},{"pmid":"36466822","id":"PMC_36466822","title":"Diagnostic and therapeutic potential of RNASET2 in Crohn's disease: Disease-risk polymorphism modulates allelic-imbalance in expression and circulating protein levels and recombinant-RNASET2 attenuates pro-inflammatory cytokine secretion.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36466822","citation_count":5,"is_preprint":false},{"pmid":"38753517","id":"PMC_38753517","title":"Macrophage transplantation rescues RNASET2-deficient leukodystrophy by replacing deficient microglia in a zebrafish model.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38753517","citation_count":5,"is_preprint":false},{"pmid":"39500942","id":"PMC_39500942","title":"Regulation of neutrophil associated RNASET2 expression in rheumatoid arthritis.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39500942","citation_count":4,"is_preprint":false},{"pmid":"25663099","id":"PMC_25663099","title":"New Strategies for Expression and Purification of Recombinant Human RNASET2 Protein in Pichia pastoris.","date":"2015","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/25663099","citation_count":3,"is_preprint":false},{"pmid":"37633478","id":"PMC_37633478","title":"Musashi-2 binds with Fbxo6 to induce Rnaset2 ubiquitination and chemokine signaling pathway during vascular smooth muscle cell phenotypic switch in atherosclerosis.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/37633478","citation_count":3,"is_preprint":false},{"pmid":"39190478","id":"PMC_39190478","title":"Exploring the role of RNASET2 in the immune response of black soldier fly larvae.","date":"2024","source":"Archives of insect biochemistry and physiology","url":"https://pubmed.ncbi.nlm.nih.gov/39190478","citation_count":3,"is_preprint":false},{"pmid":"38431116","id":"PMC_38431116","title":"Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38431116","citation_count":2,"is_preprint":false},{"pmid":"39930075","id":"PMC_39930075","title":"A Multi-omic study integrating plasma protein, multiple tissues, and single-cell identifies RNASET2 as a key gene for lung cancer.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39930075","citation_count":2,"is_preprint":false},{"pmid":"32450138","id":"PMC_32450138","title":"Expression and purification of the human tumor suppressor protein RNASET2 in CHO-S cells.","date":"2020","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/32450138","citation_count":1,"is_preprint":false},{"pmid":"24327149","id":"PMC_24327149","title":"[Association of RNASET2 gene polymorphisms and haplotypes with Graves disease in Han Chinese population from coastal regions of Shandong].","date":"2013","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24327149","citation_count":1,"is_preprint":false},{"pmid":"40389981","id":"PMC_40389981","title":"The human RNASET2 alarmin-like molecule differentially affects prostate cancer cells behavior in both cell autonomous and non-cell autonomous manners.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40389981","citation_count":0,"is_preprint":false},{"pmid":"41704487","id":"PMC_41704487","title":"Integrative multi-omics Mendelian randomization and functional validation identifies RNASET2 as a novel therapeutic target for autoimmune thyroiditis.","date":"2026","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/41704487","citation_count":0,"is_preprint":false},{"pmid":"29336640","id":"PMC_29336640","title":"Novel RNASET2 Pathogenic Variants in an East Asian Child with Delayed Psychomotor Development.","date":"2018","source":"Fetal and pediatric pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29336640","citation_count":0,"is_preprint":false},{"pmid":"41453865","id":"PMC_41453865","title":"Unlocking microglia pyroptosis in a model of type I interferon-driven neuroinflammation: lessons from Rnaset2-/- mice.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41453865","citation_count":0,"is_preprint":false},{"pmid":"41980967","id":"PMC_41980967","title":"Restorative macrophage-derived RNAseT2 stimulates muscle stem cell fusion via an SLK/N-WASP/actin bundling dependent axis.","date":"2026","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41980967","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.20.683168","title":"Interleukin-36 upregulates type-I interferon responses in systemic lupus erythematosus by promoting the accumulation of self-nucleic acids","date":"2025-10-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.20.683168","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.09.674968","title":"Lysosomal RNA profiling reveals targeting of specific types of RNAs for degradation","date":"2025-09-09","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.09.674968","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.11.612435","title":"Macrophage-derived RNAseT2 stimulates muscle stem cell fusion via SLK/N-WASP/actin bundling","date":"2024-09-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.11.612435","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.14.648817","title":"tRNA-derived RNA processing in sperm transmits non-genetically inherited phenotypes to offspring in  <i>C. elegans</i>","date":"2025-04-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.14.648817","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34917,"output_tokens":6697,"usd":0.102603,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15677,"output_tokens":5430,"usd":0.107067,"stage2_stop_reason":"end_turn"},"total_usd":0.20967,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"RNASET2 is an acidic endoribonuclease with demonstrated catalytic (RNase) activity, as shown using purified recombinant protein expressed in the Baculovirus Expression Vector System and in a human cell line. The protein exists in multiple forms including a full-length glycosylated secreted form and proteolytic products, and localizes to lysosomes.\",\n      \"method\": \"Recombinant protein expression, enzymatic activity assay, subcellular fractionation/localization\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with purified recombinant protein, lysosomal localization by direct experiment, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16620762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RNASET2 suppresses tumorigenesis and metastasis in ovarian cancer cell lines in vivo; this activity is not dependent on ribonuclease catalytic activity, as a double point mutation at the putative catalytic sites did not abolish tumor/metastasis suppression.\",\n      \"method\": \"In vivo xenograft assay, site-directed mutagenesis of catalytic residues, metastasis assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site mutagenesis with in vivo functional readout, single lab, replicated in subsequent papers\",\n      \"pmids\": [\"15809705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Recombinant RNASET2 binds actin in vitro and inhibits angiogenesis (tube formation) induced by angiogenin, bFGF, and VEGF in HUVE cells; its antitumorigenic activity in colony formation assays is independent of enzymatic activity (catalytically inactive EI-RNASET2 retains this activity).\",\n      \"method\": \"Actin-binding assay (membrane blotting, crosslinking), HUVE cell tube formation assay, colony formation assay with enzymatically inactivated protein, xenograft model\",\n      \"journal\": \"Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal assays (binding, angiogenesis, colony formation, in vivo), single lab\",\n      \"pmids\": [\"17109444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RNASET2 controls ovarian tumorigenesis in vivo through modification of the cellular microenvironment by inducing recruitment of immunocompetent cells of the monocyte/macrophage lineage; no direct effect on cancer cells was detected in several in vitro assays.\",\n      \"method\": \"In vivo xenograft tumor assay, in vitro functional assays (negative), immune cell recruitment analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo functional assay with immune cell characterization, single lab, multiple methods\",\n      \"pmids\": [\"21189302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RNASET2 localizes to lysosomes in neurons; loss of rnaset2 in zebrafish leads to accumulation of undigested rRNA within lysosomes in brain neurons, white matter lesions, and accumulation of Amyloid precursor protein at sites of neurodegeneration, establishing familial cystic leukoencephalopathy as a lysosomal storage disorder with rRNA as the storage substrate.\",\n      \"method\": \"Zebrafish genetic mutant model, lysosomal localization by imaging, MRI microimaging, immunohistochemistry for APP and astrocyte markers\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in vertebrate model with multiple orthogonal readouts (lysosomal localization, rRNA accumulation, MRI, IHC), replicated across labs\",\n      \"pmids\": [\"21199949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RNASET2 traffics through the trans-Golgi network and undergoes delivery to the plasma membrane for secretion. A second intracellular pool co-localizes with P-bodies, and this co-localization increases upon metabolic stress. Cells lacking RNASET2 show reduced numbers of P-bodies, indicating RNASET2 is involved in P-body formation.\",\n      \"method\": \"Fluorescence microscopy co-localization with TGN, plasma membrane, and P-body markers; temperature-sensitive VSVG trafficking assay; RNASET2 knockdown with P-body counting\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell imaging with multiple markers and functional loss-of-function, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"22188480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Overexpression of RNASET2 in melanocytes induces apoptosis via the TRAF2-caspases pathway; RNASET2 physically interacts with TRAF2, and overexpression inhibits TRAF2 expression.\",\n      \"method\": \"Overexpression in primary melanocytes, apoptosis assays (caspase pathway), co-immunoprecipitation of RNASET2-TRAF2 interaction\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP interaction plus overexpression functional assay, single lab, two methods\",\n      \"pmids\": [\"24457966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RNASET2 is required for lipotoxic and oxidative stress-mediated cell death; haploinsufficiency confers increased antioxidant capacity and resistance to ROS-induced death. This function is critically dependent on catalytic activity (unlike its antitumorigenic role). Knockdown of RNASET2 in Drosophila fat body increases survival under oxidative stress.\",\n      \"method\": \"Loss-of-function genetic screen, haploinsufficiency experiments, ROS assays, knockdown in Drosophila (model organism ortholog)\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic screen plus in vivo Drosophila knockdown, catalytic-activity dependence established, single lab\",\n      \"pmids\": [\"26206090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Mammalian mitochondrial RNA degradation occurs in the mitochondrial intermembrane space (IMS), not the matrix, and is carried out by IMS-localized RNASET2.\",\n      \"method\": \"Biochemical fractionation of mitochondrial compartments, knockdown and overexpression in HEK293 cells, RNA decay assays\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — biochemical reconstitution with fractionation plus genetic knockdown/overexpression, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"28730546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Mitochondrial IMS RNASET2 also selectively degrades cytosolic rRNAs associated with the mitochondrial outer membrane; this degradation activity positively affects nuclear transcription of rRNAs (compensatory feedback) and influences protein translation inside and outside mitochondria.\",\n      \"method\": \"Biochemical fractionation, rRNA decay measurements, genetic knockdown and overexpression in HEK293 and mouse cells, protein translation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal biochemical and genetic methods in two cell systems, single lab, mechanistically novel extension of prior finding\",\n      \"pmids\": [\"30385512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RNASET2 impairs sperm motility by interacting with AKAP4 in the sperm tail, reducing PKA activity, PI3K activity, and intracellular calcium levels; cAMP supplementation rescues motility.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, co-localization by confocal microscopy, RNASET2 protein incubation assay, PKA/PI3K/calcium measurement\",\n      \"journal\": \"Reproduction (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus MS identification plus functional rescue by cAMP, single lab, multiple methods\",\n      \"pmids\": [\"29581387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FBXO6, a substrate recognition subunit of an SCF E3 ubiquitin ligase complex, directly interacts with RNASET2 and promotes its K48-linked polyubiquitination via its FBA domain, leading to proteasomal degradation of RNASET2.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, domain mapping (FBA domain), proteasome inhibitor experiments, clinical sample correlation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct ubiquitination assay with domain mapping, co-IP, and proteasome dependence established, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33767133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Rnaset2-/- mice (CRISPR/Cas9-generated) exhibit upregulation of interferon-stimulated genes and IFNAR1-dependent neuroinflammation, with infiltration of CD8+ effector memory T cells and inflammatory monocytes into grey and white matter; single-nuclei RNA sequencing revealed homeostatic dysfunctions in glial cells and neurons.\",\n      \"method\": \"CRISPR/Cas9 knockout mice, ISG expression profiling, immune cell characterization by flow cytometry/IHC, IFNAR1 blocking, single-nuclei RNA sequencing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout model with multiple independent readouts including snRNA-seq and IFNAR1 blocking epistasis, rigorous study\",\n      \"pmids\": [\"34764281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Mutant microglia (in rnaset2-deficient zebrafish) display engorged morphology filled with undigested apoptotic cells and undigested substrate; microglia-specific depletion and rescue experiments identified microglia as the cellular driver of the embryonic neuroinflammatory phenotype in RNASET2-deficient leukoencephalopathy.\",\n      \"method\": \"Zebrafish mutant model, live confocal imaging, electron microscopy, microglia-specific depletion and macrophage rescue experiments\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic model with live imaging, EM, and cell-specific rescue experiments, rigorous mechanistic dissection\",\n      \"pmids\": [\"32212285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RNASET2 expression increases following stress induction; changes in RNASET2 levels affect actin cytoskeleton organization, cell adhesion, and motility in ovarian cancer cells in vitro, suggesting cell-autonomous oncosuppressive mechanisms distinct from its microenvironmental role.\",\n      \"method\": \"Stress induction assays, overexpression/knockdown in ovarian cancer cells, actin cytoskeleton imaging, cell adhesion and motility assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple cell biological readouts, single lab, but indirect mechanism\",\n      \"pmids\": [\"25797262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RNASET2 interacts with shootin1 (an axon outgrowth protein) in vitro as identified by human proteome microarray and confirmed by co-immunoprecipitation; recombinant RNASET2 alters actin network organization in melanocytes and inhibits A375 cell migration.\",\n      \"method\": \"Human proteome microarray, co-immunoprecipitation, actin network imaging, cell migration assay\",\n      \"journal\": \"Journal of dermatological science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — proteome microarray identification with Co-IP confirmation and functional assays, single lab\",\n      \"pmids\": [\"26293343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A truncated RNASET2 lacking RNase activity (trT2-50, starting at E50) retains actin-binding activity and inhibits angiogenesis and tumorigenesis; trT2-50 binds cell-surface actin and forms a complex with actin in vitro, co-localizes with angiogenin, and disrupts the intracellular actin network of HUVECs.\",\n      \"method\": \"Truncation mutagenesis, in vitro actin-binding assay, HUVE cell tube formation assay, immunofluorescence, xenograft tumor assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of actin binding with truncation mutant plus functional assays, single lab\",\n      \"pmids\": [\"25426551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RNASET2 protein affects macrophage polarization in vitro, promoting a shift toward M1-like (anti-tumor) phenotype and away from M2-like phenotype, as demonstrated by in vitro macrophage polarization assays.\",\n      \"method\": \"In vitro macrophage polarization assay with recombinant RNASET2, transcriptional profiling of M1/M2 markers\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — in vitro assay with recombinant protein, single lab, functional readout with multiple markers\",\n      \"pmids\": [\"30218741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Murine Rnaset2 overexpression in syngeneic tumor models leads to recruitment of CD86+ M1 macrophages, inhibition of MDSCs and M2 macrophages, subsequent expansion of intratumoral CD8+ T cells, and long-term tumor rejection with T cell memory response upon re-challenge.\",\n      \"method\": \"Syngeneic mouse tumor model, immune cell phenotyping by flow cytometry, re-challenge assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo syngeneic model with immune cell characterization and re-challenge, single lab\",\n      \"pmids\": [\"32197460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RNASET2 deficiency leads to accumulation of cholesterol by hindering RNA degradation into uridine, reducing UTP levels, restraining glucuronate metabolism and UDP-glucuronosyltransferase (UGT1A1) expression, causing decreased bile acid glucuronidation and cholesterol accumulation. Accumulated cholesterol promotes MET receptor-mediated HCC metastasis, which can be reversed by MET knockdown or savolitinib.\",\n      \"method\": \"RNASET2 knockout cells and mouse models, metabolomics (uridine/UTP/glucuronate measurement), UGT1A1 expression analysis, cholesterol measurement, MET activation assay, shRNA/pharmacological MET inhibition rescue\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-step metabolic pathway established with genetic KO plus rescue experiments, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39903758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MSI2 (Musashi-2) binds FBXO6 to induce Rnaset2 ubiquitination; MSI2 knockdown inhibits VSMC proliferation and migration and suppresses chemokine signaling via the FBXO6/Rnaset2 axis in atherosclerosis.\",\n      \"method\": \"RNA-binding protein immunoprecipitation, co-immunoprecipitation, siRNA knockdown, proliferation/migration assays, in vivo atherosclerosis mouse model\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and Co-IP with functional rescue, single lab\",\n      \"pmids\": [\"37633478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RNASET2 expression in epithelial ovarian cancer cells negatively affects growth capability by altering cell interaction with the extracellular matrix, resulting in decreased Src kinase activation, as shown by RNASET2 silencing and overexpression experiments.\",\n      \"method\": \"RNASET2 silencing and overexpression in EOC cell lines, Src activation assay (phospho-Src), ECM adhesion and growth assays\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — loss- and gain-of-function with defined signaling readout (Src), single lab\",\n      \"pmids\": [\"30813308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hypoxia enhances RNASET2 expression and secretion in human monocyte-derived dendritic cells via the PI3K/AKT pathway; this expression is almost completely abolished by TLR4 ligand LPS, and parallels HIF-1α accumulation.\",\n      \"method\": \"Hypoxia treatment of primary DCs, RNASET2 ELISA, PI3K/AKT inhibitor experiments, HIF-1α measurement\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological pathway dissection plus secretion measurement, single lab\",\n      \"pmids\": [\"34299186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Macrophage-secreted RNASET2 enters muscle stem cells (MuSCs) via the mannose receptor, binds to SLK (Ste20-like kinase), which triggers phosphorylation-mediated activation of N-WASP through Paxillin phosphorylation, enabling actin bundling required for MuSC fusion; macrophages deficient in RNAseT2 show fusion defects and smaller myofibers in vivo.\",\n      \"method\": \"Recombinant protein treatment, mannose receptor blocking, co-immunoprecipitation of RNASET2-SLK interaction, N-WASP/Paxillin phosphorylation assays, macrophage-specific knockout in mouse and zebrafish, in vivo overexpression\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical interaction (Co-IP), receptor-mediated entry, kinase pathway mutagenesis, in vivo rescue in two model organisms, multiple orthogonal methods\",\n      \"pmids\": [\"41980967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RNASET2 is identified as a lysosomal RNase; cells lacking RNASET2 (together with PLD3 and RNase A family members) accumulate large amounts of lysosomal RNA, establishing RNASET2 as one of the enzymatic effectors of lysosomal RNA degradation.\",\n      \"method\": \"Lysosomal fractionation and RNA profiling, genetic knockout of RNASET2 and other lysosomal RNases, RNA accumulation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with direct lysosomal RNA measurement, preprint, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Transplanted macrophages engraft in rnaset2-deficient zebrafish brains, adopt a microglial phenotype, clear apoptotic cells, rescue antiviral immune overactivation (confirmed by RNA sequencing), and restore normal motor behavior, establishing microglia as the cellular driver of neuropathology in RNASET2 deficiency.\",\n      \"method\": \"Macrophage transplantation into zebrafish embryos, live imaging, tissue clearing, RNA sequencing, behavioral assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-specific rescue with multiple readouts (imaging, transcriptomics, behavior), rigorous mechanistic attribution to microglia\",\n      \"pmids\": [\"38753517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RNASET2 is localized in primary and tertiary granules of neutrophils and is released in association with neutrophil extracellular traps (NETs) upon PMA, Nigericin, or soluble immune complex stimulation.\",\n      \"method\": \"Immunofluorescence co-localization with granule markers, NET induction assays, co-localization of RNASET2 with NET markers\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct co-localization experiments with multiple stimuli, single lab\",\n      \"pmids\": [\"39500942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Recombinant RNASET2 reduces IFN-γ secretion in T cells when added exogenously or overexpressed; disease-risk variant rs2149092 affects allele-specific RNASET2 expression through transcriptional and post-transcriptional mechanisms.\",\n      \"method\": \"T cell activation assays, RNASET2 overexpression and recombinant protein treatment, cytokine ELISA, allele-specific expression assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function and recombinant protein with cytokine readout, single lab\",\n      \"pmids\": [\"36466822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RNASET2 knockdown in a 3D inflammatory thyrocyte spheroid model heightens susceptibility to inflammatory cell death and cytokine expression; recombinant RNASET2 rescue mitigates inflammation and apoptosis, confirming a functional protective role.\",\n      \"method\": \"siRNA knockdown, recombinant RNASET2 rescue, 3D spheroid inflammatory model, apoptosis and cytokine assays\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with protein rescue in defined model, single lab, two orthogonal approaches\",\n      \"pmids\": [\"41704487\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RNASET2 is an evolutionarily conserved, lysosome- and IMS-localized acidic endoribonuclease that degrades rRNA, mitochondrial RNA, and cytosolic rRNAs on the mitochondrial outer membrane; its catalytic activity is required for lysosomal RNA homeostasis and ROS-dependent cell death, but dispensable for its tumor-suppressive and antiangiogenic functions, which instead operate through actin cytoskeleton remodeling (via SLK/N-WASP activation and actin binding), ECM-mediated Src signaling suppression, recruitment and M1 polarization of macrophages, TRAF2-caspase apoptosis induction, and modulation of T cell IFN-γ; RNASET2 protein stability is regulated by FBXO6-mediated K48-linked ubiquitination and proteasomal degradation, and its deficiency in neurons causes lysosomal rRNA accumulation, microglial dysfunction, and an IFNAR1-dependent type I interferon-driven leukoencephalopathy.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RNASET2 is an evolutionarily conserved acidic endoribonuclease that degrades RNA in multiple subcellular compartments and underpins both intracellular RNA homeostasis and a set of catalysis-independent extracellular signaling functions [#0, #1]. As an enzyme, it is a glycosylated, secreted RNase that localizes to lysosomes [#0] and functions as an effector of lysosomal RNA degradation; its loss causes accumulation of undigested rRNA within neuronal lysosomes, defining RNASET2-deficient cystic leukoencephalopathy as a lysosomal storage disorder with rRNA as the storage substrate [#4]. A distinct pool resides in the mitochondrial intermembrane space, where it degrades mitochondrial RNA and outer-membrane-associated cytosolic rRNAs, feeding back on nuclear rRNA transcription and translation [#8, #9]. This catalytic activity is required for lipotoxic/oxidative-stress-mediated cell death [#7] but is dispensable for RNASET2's tumor- and metastasis-suppressive and antiangiogenic activities, which instead depend on actin binding: catalytically inactive and N-terminally truncated forms retain actin-binding, antiangiogenic, and antitumorigenic activity [#1, #2, #16]. Secreted RNASET2 acts non-cell-autonomously to remodel the tumor and tissue microenvironment, suppressing Src signaling through altered ECM interaction [#21], recruiting monocyte/macrophages and driving M1 polarization with downstream CD8+ T cell expansion and tumor rejection [#3, #18], and entering recipient cells via the mannose receptor to bind SLK and activate N-WASP-dependent actin bundling required for muscle stem cell fusion [#23]. RNASET2 protein abundance is controlled by FBXO6, which directly binds it and catalyzes K48-linked polyubiquitination and proteasomal degradation [#11]. In the nervous system, RNASET2 deficiency produces engorged, dysfunctional microglia that fail to clear apoptotic substrate and drive an IFNAR1-dependent type I interferon neuroinflammation, with microglia established as the cellular driver via cell-specific depletion and macrophage rescue [#12, #13, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that RNASET2's tumor- and metastasis-suppressive activity is separable from its predicted enzymatic role, a finding that reframed the protein as more than an RNase.\",\n      \"evidence\": \"in vivo ovarian cancer xenograft and metastasis assays with catalytic-site double point mutants\",\n      \"pmids\": [\"15809705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the molecular mediator of catalysis-independent suppression\", \"Mechanism of microenvironmental action not yet defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Confirmed RNASET2 is a bona fide acidic endoribonuclease and a glycosylated, secreted, lysosomally localized protein, anchoring its enzymatic and trafficking identity.\",\n      \"evidence\": \"purified recombinant protein enzymatic assay plus subcellular fractionation/localization\",\n      \"pmids\": [\"16620762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo RNA substrates not defined\", \"Relationship between secreted and lysosomal pools unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified actin binding as a candidate catalysis-independent effector mechanism by showing RNASET2 binds actin and inhibits angiogenesis induced by multiple growth factors.\",\n      \"evidence\": \"in vitro actin-binding assays, HUVE tube formation, colony formation with enzymatically inactivated protein, xenografts\",\n      \"pmids\": [\"17109444\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not map the actin-binding region\", \"Link between actin binding and antiangiogenesis correlative\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed the oncosuppressive effect operates non-cell-autonomously through recruitment of monocyte/macrophage-lineage immune cells, identifying a microenvironmental mechanism.\",\n      \"evidence\": \"in vivo ovarian xenografts with immune cell recruitment analysis and negative in vitro cancer-cell assays\",\n      \"pmids\": [\"21189302\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Macrophage polarization state not yet characterized\", \"Signal recruiting immune cells unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established RNASET2 deficiency as a lysosomal storage disorder by showing loss causes accumulation of undigested rRNA in neuronal lysosomes with white matter pathology.\",\n      \"evidence\": \"zebrafish genetic mutant with lysosomal imaging, MRI microimaging, and APP/astrocyte IHC\",\n      \"pmids\": [\"21199949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular driver of neuropathology not yet pinpointed\", \"Inflammatory mechanism not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extended RNASET2 localization to the secretory pathway and P-bodies, linking it to cytoplasmic RNA granule biology under metabolic stress.\",\n      \"evidence\": \"fluorescence co-localization with TGN/PM/P-body markers, VSVG trafficking, and knockdown P-body counting\",\n      \"pmids\": [\"22188480\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of P-body involvement undefined\", \"Does not connect P-body role to enzymatic or microenvironmental functions\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated a pro-apoptotic activity via direct TRAF2 interaction, and confirmed actin remodeling by an RNase-dead truncation, separating catalytic from cytoskeletal functions in melanocytes.\",\n      \"evidence\": \"overexpression apoptosis assays with TRAF2 Co-IP; truncation mutagenesis with in vitro actin-binding and angiogenesis/tumor assays\",\n      \"pmids\": [\"24457966\", \"25426551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRAF2 interaction shown by single Co-IP without structural detail\", \"Physiological context of TRAF2-caspase axis unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a catalysis-dependent function in stress-induced cell death and connected RNASET2 levels to actin organization, adhesion, and motility, splitting its activities into distinct mechanistic branches.\",\n      \"evidence\": \"loss-of-function/haploinsufficiency ROS assays, Drosophila fat-body knockdown; ovarian cancer cell actin/adhesion/motility assays; shootin1 interaction by proteome microarray and Co-IP\",\n      \"pmids\": [\"26206090\", \"25797262\", \"26293343\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate driving ROS-dependent death not identified\", \"Mechanistic link between shootin1/actin binding and motility incomplete\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Localized a functional pool of RNASET2 to the mitochondrial intermembrane space and assigned it responsibility for mitochondrial RNA degradation, revealing an unexpected mitochondrial compartment role.\",\n      \"evidence\": \"mitochondrial sub-compartment fractionation with knockdown/overexpression and RNA decay assays in HEK293\",\n      \"pmids\": [\"28730546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import mechanism into IMS unknown\", \"Regulation of compartment-specific targeting undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded mitochondrial RNASET2's role to degradation of outer-membrane-associated cytosolic rRNAs with compensatory feedback on nuclear rRNA transcription and translation, linking it to global RNA economy.\",\n      \"evidence\": \"fractionation, rRNA decay measurements, knockdown/overexpression in HEK293 and mouse cells, translation assays\",\n      \"pmids\": [\"30385512\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of feedback to nuclear transcription not resolved\", \"Selectivity for OMM-associated rRNAs not explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected RNASET2 to macrophage polarization and a sperm-tail AKAP4 signaling axis, broadening its extracellular and tissue-specific functional repertoire.\",\n      \"evidence\": \"in vitro macrophage M1/M2 polarization with recombinant protein; sperm Co-IP/MS with AKAP4 and PKA/PI3K/calcium readouts plus cAMP rescue\",\n      \"pmids\": [\"30218741\", \"29581387\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating macrophage effect not identified here\", \"Physiological relevance of sperm AKAP4 interaction unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified an ECM-dependent, cell-autonomous oncosuppressive branch acting through reduced Src kinase activation, refining the non-enzymatic mechanism.\",\n      \"evidence\": \"silencing/overexpression in EOC lines with phospho-Src, ECM adhesion, and growth assays\",\n      \"pmids\": [\"30813308\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between RNASET2 and ECM not defined\", \"Connection to actin-binding branch not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated in vivo that RNASET2 drives M1 macrophage recruitment, MDSC/M2 suppression, CD8+ T cell expansion, and durable immune memory, and established microglia as the cellular driver of leukoencephalopathy.\",\n      \"evidence\": \"syngeneic mouse tumor model with immune phenotyping and re-challenge; zebrafish microglia-specific depletion/rescue with live imaging and EM\",\n      \"pmids\": [\"32197460\", \"32212285\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signal for immune recruitment unresolved\", \"Whether tumor and CNS macrophage roles share a mechanism unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined post-translational control of RNASET2 abundance via FBXO6-mediated K48 ubiquitination and proteasomal degradation, and established an IFNAR1-dependent type I interferon mechanism for the neuroinflammatory disease.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, FBA domain mapping, proteasome inhibition; CRISPR knockout mice with ISG profiling, IFNAR1 blocking, and snRNA-seq\",\n      \"pmids\": [\"33767133\", \"34764281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering FBXO6 recognition not defined\", \"Source of the interferon-stimulating ligand (accumulated RNA) not directly proven\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected RNASET2 enzymatic RNA degradation to a uridine-glucuronate-cholesterol metabolic axis driving MET-dependent HCC metastasis, and placed the FBXO6/RNASET2 axis under MSI2 control in vascular disease.\",\n      \"evidence\": \"KO cells/mice with metabolomics, UGT1A1 and cholesterol analysis, MET inhibition rescue; RIP/Co-IP and atherosclerosis mouse model for MSI2-FBXO6\",\n      \"pmids\": [\"39903758\", \"37633478\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of RNA-derived uridine to cholesterol pool uncertain\", \"Tissue specificity of MSI2/FBXO6 regulation not generalized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved a receptor-to-cytoskeleton signaling pathway: macrophage-secreted RNASET2 enters target cells via the mannose receptor and binds SLK to activate N-WASP-driven actin bundling required for muscle stem cell fusion, and confirmed microglial rescue of CNS pathology.\",\n      \"evidence\": \"recombinant protein, mannose receptor blocking, RNASET2-SLK Co-IP, N-WASP/Paxillin phospho assays, macrophage-specific KO in mouse and zebrafish; macrophage transplantation into zebrafish with imaging, RNA-seq, behavior\",\n      \"pmids\": [\"41980967\", \"38753517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the SLK/N-WASP pathway underlies the antitumor actin functions not tested\", \"Structural basis of RNASET2-SLK interaction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how RNASET2 partitions between its catalysis-dependent RNA-homeostasis roles and its catalysis-independent secreted signaling functions, and whether a unifying molecular trigger directs the protein to lysosome, mitochondrial IMS, or extracellular signaling fates.\",\n      \"evidence\": \"no single study in the corpus reconciles the compartment-specific and catalysis-independent activities\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model linking actin/SLK binding to catalytic domain\", \"Mechanism directing subcellular partitioning unknown\", \"Identity of the immunostimulatory RNA species in disease not directly defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 8, 9, 24]},\n      {\"term_id\": \"GO:0004540\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [2, 16]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 4, 24]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 23, 26]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [8, 9, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 12, 18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TRAF2\", \"FBXO6\", \"AKAP4\", \"SLK\", \"SHTN1\", \"MSI2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}